The Relationships Among Physiologic Variables, Quality of Life, and Fatigue in Patients With Multiple Myeloma

Reanne Booker

Karin Olson

Linda M. Pilarski

Joseph P. Noon

Nizar J. Bahlis

quality of life, multiple myeloma, fatigue
ONF 2009, 36(2), 209-216. DOI: 10.1188/09.ONF.209-216

Purpose/Objectives: To investigate the relationships among physiologic variables, fatigue, and quality of life (QOL) in patients with multiple myeloma.

Design: Cross-sectional, descriptive, exploratory.

Setting: Outpatient ambulatory care clinics at a tertiary oncology center.

Sample: 56 patients with multiple myeloma were accrued consecutively via nonprobability sampling strategy.

Methods: Study participants completed the European Organisation for Research and Treatment of Cancer QLQ-C30 and the Functional Assessment of Cancer Therapy-Fatigue. Physiologic variables and demographic data were collected from patient charts.

Main Research Variables: Hemoglobin (hgb), C-reactive protein (CRP), fatigue, and QOL.

Findings: Statistically significant correlations were found among hgb and two measures of fatigue and QOL, as well as among CRP and two measures of fatigue and QOL. Regression analysis revealed that as soon as the effect of CRP was removed, hgb was no longer a significant predictor of fatigue or QOL.

Conclusions: Although significant relationships between hgb and fatigue and hgb and QOL were identified, CRP made a significant contribution to predicting the variance in fatigue and QOL, whereas hgb did not. The findings suggest that higher CRP is predictive of greater fatigue and lower QOL.

Implications for Nursing: Nurses play an integral role in the assessment and management of cancer-related fatigue. Greater understanding of the pathophysiology of fatigue may lead to progress in assessment and intervention, with the ultimate goal of reducing cancer-related fatigue and improving QOL.

Jump to a section


    Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., et al. (1993). The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(5), 365-376.
    Ahlberg, K., Ekman, T., & Gaston-Johansson, F. (2004). Levels of fatigue compared to levels of cytokines and hemoglobin during pelvic radiotherapy: A pilot study. Biological Research for Nursing, 5(3), 203-210.
    Ahlberg, K., Ekman, T., Gaston-Johansson, F., & Mock, V. (2003). Assessment and management of cancer-related fatigue in adults. Lancet, 362(9384), 640-650.
    Alberta Cancer Board. (2004). Research protocol approval application for science and ethics. Retrieved August 10, 2004, from
    Andrews, N. C. (2004). Anemia of inflammation: The cytokine-hepcidin link. Journal of Clinical Investigation, 113(9), 1251-1253.
    Barnes, E. A., & Bruera, E. (2002). Fatigue in patients with advanced cancer: A review. International Journal of Gynecological Cancer, 12(5), 424-428.
    Bataille, R., Barlogie, B., Lu, Z. Y., Rossi, J. F., Lavabre-Bertrand, T., Beck, T., et al. (1995). Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood, 86(2), 685-691.
    Bohlius, J., Wilson, J., Seidenfeld, J., Piper, M., Schwarzer, G., Sandercock, J., et al. (2006). Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. Journal of the National Cancer Institute, 98(10), 708-714.
    Bower, J. E., Ganz, P. A., Desmond, K. A., Rowland, J. H., Meyerowitz, B. E., & Belin, T. R. (2000). Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. Journal of Clinical Oncology, 18(4), 743-753.
    Brown, D. J., McMillan, D. C., & Milroy, R. (2005). The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. Cancer, 103(2), 377-382.
    Clearfield, M. B. (2005). C-reactive protein: A new risk assessment tool for cardiovascular disease. Journal of the American Osteopathic Association, 105(9), 409-416.
    Collado-Hidalgo, A., Bower, J. E., Ganz, P. A., Cole, S. W., & Irwin, M. R. (2006). Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clinical Cancer Research, 12(9), 2759-2766.
    Dimeo, F., Schmittel, A., Fietz, T., Schwartz, S., Kohler, P., Boning, D., et al. (2004). Physical performance, depression, immune status and fatigue in patients with hematological malignancies after treatment. Annals of Oncology, 15(8), 1237-1242.
    Durie, B. G., Kyle, R. A., Belch, A., Bensinger, W., Blade, J., Boccadoro, M., et al. (2003). Myeloma management guidelines: A consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematology Journal, 4(6), 379-398.
    Gutstein, H. B. (2001). The biologic basis of fatigue. Cancer, 92(6, Suppl.), 1678-1683.
    Hair, J. F., Anderson, R. E., Tatham, R. L., & Black, W. C. (1998). Multivariate data analysis (5th ed.). Upper Saddle River, NJ: Prentice Hall.
    Harousseau, J. L., & Moreau, P. (2002). Prognostic factors in myeloma. In J. Mehta & S. Singhal (Eds.), Myeloma (pp. 169-183). London: Martin Dunitz.
    Hideshima, T., Bergsagel, P. L., Kuehl, W. M., & Anderson, K. C. (2004). Advances in biology of multiple myeloma: Clinical applications. Blood, 104(3), 607-618.
    Holzner, B., Kemmler, G., Greil, R., Kopp, M., Zeimet, A., Raderer, M., et al. (2002). The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Annals of Oncology, 13(6), 965-973.
    Illman, J., Corringham, R., Robinson, D., Jr., Davis, H. M., Rossi, J. F., Cella, D., et al. (2005). Are inflammatory cytokines the common link between cancer-associated cachexia and depression? Journal of Supportive Oncology, 3(1), 37-50.
    Kurzrock, R. (2001). The role of cytokines in cancer-related fatigue. Cancer, 92(6, Suppl.), 1684-1688.
    Kyle, R. A., Gertz, M. A., Witzig, T. E., Lust, J. A., Lacy, M. Q., Dispenzieri, A., et al. (2003). Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 78(1), 21-33.
    Lee, B. N., Dantzer, R., Langley, K. E., Bennett, G. J., Dougherty, P. M., Dunn, A. J., et al. (2004). A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation, 11(5), 279-292.
    Lind, M., Vernon, C., Cruickshank, D., Wilkinson, P., Littlewood, T., Stuart, N., et al. (2002). The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. British Journal of Cancer, 86(8), 1243-1249.
    Ludwig, H., Rai, K., Blade, J., Dammacco, F., Degos, L., Itri, L., et al. (2002). Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: Epoetin treatment recommendations. Hematology Journal, 3(3), 121-130.
    Maccio, A., Madeddu, C., Massa, D., Mudu, M. C., Lusso, M. R., Gramignano, G., et al. (2005). Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: Role of inflammation in cancer-related anemia. Blood, 106(1), 362-367.
    Mazhar, D., Gillmore, R., & Waxman, J. (2005). COX and cancer. QJM: An International Journal of Medicine, 98(10), 711-718.
    Morrow, G. R., Andrews, P. L., Hickok, J. T., Roscoe, J. A., & Matteson, S. (2002). Fatigue associated with cancer and its treatment. Supportive Care in Cancer, 10(5), 389-398.
    Morrow, G. R., Shelke, A. R., Roscoe, J. A., Hickok, J. T., & Mustian, K. (2005). Management of cancer-related fatigue. Cancer Investigation, 23(3), 229-239.
    National Comprehensive Cancer Network. (2008). NCCN Clinical Practice Guidelines in Oncology™: Cancer-related fatigue [v.1.2008]. Retrieved January 22, 2009, from
    Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., et al. (2004). IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. Journal of Clinical Investigation, 113(9), 1271-1276.
    Olson, K., & Morse, J. (2005). Delineating the concept of fatigue using a pragmatic utility approach. In J. Cutcliff & H. McKenna (Eds.), The essential concepts of nursing (pp. 141-159). Oxford, England: Elsevier Science.
    Olson, K., Tom, B., Hewitt, J., Whittingham, J., Buchanan, L., & Ganton, G. (2002). Evolving routines: Preventing fatigue associated with lung and colorectal cancer. Qualitative Health Research, 12(5), 655-670.
    Olson, K., Turner, A. R., Courneya, K. S., Field, C., Man, G., Cree, M., et al. (2008). Possible links between behavioral and physiological indices of tiredness, fatigue, and exhaustion in advanced cancer. Supportive Care in Cancer, 16(3), 241-249.
    Osoba, D., Aaronson, N., Zee, B., Sprangers, M., & te Velde, A. (1997). Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. Quality of Life Research, 6(2), 103-108.
    Palumbo, A., Bertola, A., Musto, P., Caravita, T., Callea, V., Cangialosi, C., et al. (2004). A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): An interim analysis. Blood, 104(11), 207.
    Prue, G., Rankin, J., Allen, J., Gracey, J., & Cramp, F. (2006). Cancer-related fatigue: A critical appraisal. European Journal of Cancer, 42(7), 846-863.
    Ringdal, K., Ringdal, G. I., Kaasa, S., Bjordal, K., Wisloff, F., Sundstrom, S., et al. (1999). Assessing the consistency of psychometric properties of the HRQoL scales within the EORTC QLQ-C30 across populations by means of the Mokken Scaling Model. Quality of Life Research, 8(1-2), 25-43.
    Rivera, S., Liu, L., Nemeth, E., Gabayan, V., Sorensen, O. E., & Ganz, T. (2005). Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood, 105(4), 1797-1802.
    Rossi, J. F., Fegueux, N., Lu, Z. Y., Legouffe, E., Exbrayat, C., Bozonnat, M. C., et al. (2005). Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140mg/m2 of melphalan in multiple myeloma: Results of a pilot study including biological aspects. Bone Marrow Transplantation, 36(9), 771-779.
    Ryan, J. L., Carroll, J. K., Ryan, E. P., Mustian, K. M., Fiscella, K., & Morrow, G. R. (2007). Mechanisms of cancer-related fatigue. Oncologist, 12(Suppl. 1), 22-34.
    Schubert, C., Hong, S., Natarajan, L., Mills, P. J., & Dimsdale, J. E. (2007). The association between fatigue and inflammatory marker levels in cancer patients: A quantitative review. Brain, Behavior, and Immunity, 21(4), 413-427.
    Scott, H. R., McMillan, D. C., Forrest, L. M., Brown, D. J., McArdle, C. S., & Milroy, R. (2002). The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. British Journal of Cancer, 87(3), 264-267.
    Sharma, S., Nemeth, E., Chen, Y. H., Goodnough, J., Huston, A., Roodman, G. D., et al. (2008). Involvement of hepcidin in the anemia of multiple myeloma. Clinical Cancer Research, 14(11), 3262-3267.
    Trikha, M., Corringham, R., Klein, B., & Rossi, J. F. (2003). Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clinical Cancer Research, 9(13), 4653-4665.
    Turner, R., Anglin, P., Burkes, R., Couture, F., Evans, W., Goss, G., et al. (2001). Epoetin alfa in cancer patients: Evidence-based guidelines. Journal of Pain and Symptom Management, 22(5), 954-965.
    University of Alberta. (2004). Human research—University of Alberta standards for the protection of human research participants. Retrieved January 22, 2009, from
    van Zaanen, H. C., Lokhorst, H. M., Aarden, L. A., Rensink, H. J., Warnaar, S. O., van der Lelie, J., et al. (1998). Chimaeric anti-interleukin-6 monoclonal antibodies in the treatment of advanced multiple myeloma: A phase I dose-escalating study. British Journal of Haematology, 102(3), 783-790.
    Wisloff, F., Gulbrandsen, N., Hjorth, M., Lenhoff, S., & Fayers, P. (2005). Quality of life may be affected more by disease parameters and response to therapy than by haemoglobin changes. European Journal of Haematology, 75(4), 293-298.
    Wood, L. J., Nail, L. M., Gilster, A., Winters, K. A., & Elsea, C. R. (2006). Cancer chemotherapy-related symptoms: Evidence to suggest a role for proinflammatory cytokines. Oncology Nursing Forum, 33(3), 535-542.
    Wratten, C., Kilmurray, J., Nash, S., Seldon, M., Hamilton, C. S., O'Brien, P. C., et al. (2004). Fatigue during breast radiotherapy and its relationship to biological factors. International Journal of Radiation Oncology, Biology, Physics, 59(1), 160-167.
    Yang, J., Wezeman, M., Zhang, X., Lin, P., Wang, M., Qian, J., et al. (2007). Human C-reactive protein binds activating Fcy receptors and protects myeloma tumor cells from apoptosis. Cancer Cell, 12(3), 252-265.
    Yellen, S. B., Cella, D. F., Webster, K., Blendowski, C., & Kaplan, E. (1997). Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system. Journal of Pain and Symptom Management, 13(2), 63-74.
    Yi, Q., Yang, J., Wezeman, M., Zhang, X., Qian, J., Hong, S., et al. (2007). C-reactive protein protects myeloma cells from apoptosis via activating ITAM-containing FcyRII. Haematologica, 92(Suppl. 2), PO-210.